High-resolution structures of HIV-1 reverse transcriptase/TMC278 complexes: Strategic flexibility explains potency against resistance mutations
暂无分享,去创建一个
Stephen H Hughes | Paul J Lewi | Eddy Arnold | A. D. Clark | A. Shatkin | S. Hughes | E. Arnold | P. Lewi | K. Das | Kalyan Das | Arthur D Clark | Y. Frenkel | J. Bauman | Joseph D Bauman | Aaron J Shatkin | Yulia V Frenkel | A. Clark
[1] H. M. Vinkers,et al. Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. , 2004, Journal of medicinal chemistry.
[2] Frank Goebel,et al. Short-term antiviral activity of TMC278 – a novel NNRTI – in treatment-naive HIV-1-infected subjects , 2006, AIDS.
[3] A. D. Clark,et al. Crystal structures of clinically relevant Lys103Asn/Tyr181Cys double mutant HIV-1 reverse transcriptase in complexes with ATP and non-nucleoside inhibitor HBY 097. , 2007, Journal of molecular biology.
[4] A. D. Clark,et al. Structure of unliganded HIV-1 reverse transcriptase at 2.7 A resolution: implications of conformational changes for polymerization and inhibition mechanisms. , 1996, Structure.
[5] Eddy Arnold,et al. On the detection of multiple-binding modes of ligands to proteins, from biological, structural, and modeling data , 2003, J. Comput. Aided Mol. Des..
[6] Erik De Clercq,et al. Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives , 1990, Nature.
[7] R. Hochstrasser,et al. Two-dimensional infrared spectra reveal relaxation of the nonnucleoside inhibitor TMC278 complexed with HIV-1 reverse transcriptase , 2008, Proceedings of the National Academy of Sciences.
[8] R. Pauwels. Aspects of successful drug discovery and development. , 2006, Antiviral research.
[9] Yvonne Jones,et al. High resolution structures of HIV-1 RT from four RT–inhibitor complexes , 1995, Nature Structural Biology.
[10] R. Pauwels,et al. Evolution of anti-HIV drug candidates. Part 3: Diarylpyrimidine (DAPY) analogues. , 2001, Bioorganic & medicinal chemistry letters.
[11] J. Heeres,et al. The medicinal chemistry of the DATA and DAPY series of HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs) , 2007 .
[12] Stephen H Hughes,et al. In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2- pyrimidinyl]amino]benzonitrile (R278474, rilpivirine). , 2005, Journal of medicinal chemistry.
[13] Stephen H Hughes,et al. Crystallography and the design of anti-AIDS drugs: conformational flexibility and positional adaptability are important in the design of non-nucleoside HIV-1 reverse transcriptase inhibitors. , 2005, Progress in biophysics and molecular biology.
[14] K. Hertogs,et al. Synthesis of novel diarylpyrimidine analogues and their antiviral activity against human immunodeficiency virus type 1. , 2005, Journal of medicinal chemistry.
[15] Kevin Cowtan,et al. research papers Acta Crystallographica Section D Biological , 2005 .
[16] Christophe Meyer,et al. Crystal structures for HIV-1 reverse transcriptase in complexes with three pyridinone derivatives: a new class of non-nucleoside inhibitors effective against a broad range of drug-resistant strains. , 2005, Journal of medicinal chemistry.
[17] D. Stammers,et al. Relationship of potency and resilience to drug resistant mutations for GW420867X revealed by crystal structures of inhibitor complexes for wild-type, Leu100Ile, Lys101Glu, and Tyr188Cys mutant HIV-1 reverse transcriptases. , 2007, Journal of medicinal chemistry.
[18] P P Chamberlain,et al. Crystal structures of HIV-1 reverse transcriptases mutated at codons 100, 106 and 108 and mechanisms of resistance to non-nucleoside inhibitors. , 2004, Journal of molecular biology.
[19] T. Steitz,et al. Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor. , 1992, Science.
[20] A T Brünger,et al. Recent developments for the efficient crystallographic refinement of macromolecular structures. , 1998, Current opinion in structural biology.
[21] K A Johnson,et al. Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors , 1995, Science.
[22] G. Murshudov,et al. Refinement of macromolecular structures by the maximum-likelihood method. , 1997, Acta crystallographica. Section D, Biological crystallography.
[23] A. D. Clark,et al. Crystallization of human immunodeficiency virus type 1 reverse transcriptase with and without nucleic acid substrates, inhibitors, and an antibody Fab fragment. , 1995, Methods in enzymology.
[24] Jianping Ding,et al. Review of HIV-1 reverse transcriptase three-dimensional structure : implications for drug design , 1993 .
[25] S. Sigurdsson,et al. Structural basis for the inhibitory efficacy of efavirenz (DMP-266), MSC194 and PNU142721 towards the HIV-1 RT K103N mutant. , 2002, European journal of biochemistry.
[26] D W Rodgers,et al. The structure of unliganded reverse transcriptase from the human immunodeficiency virus type 1. , 1995, Proceedings of the National Academy of Sciences of the United States of America.